The 16th Annual BIO CEO & Investor Conference assembles a select group of established biotech companies, as well as top public and private equity investors and members of the sell-side investment community, to explore the current investment landscape and opportunities in life sciences. In addition to plenary sessions and panel discussions on timely business topics and key therapeutic areas, the conference features presentations by over 130 leading biotechnology and pharmaceutical companies, as well as a number of nonprofit and venture philanthropy organizations.
Presenting companies are hand-selected for the event, and consist of a selection of mid- to large-cap established public companies from around the globe, who typically have a clinical stage program centered around therapeutics, molecular diagnostics, or a platform technology, as well as an upcoming clinical, regulatory, or corporate catalyst. The typical audience for a company presentation features public and private equity investors, as well as industry analysts, investment bankers and senior biotechnology executives.
Returning this year! A special track of presentations was created last year to feature private companies, and participants spoke to a standing-room only audience. The 16th annual event will once again feature these private companies. Presentations in this track will be 13 minutes in length, and will be reserved specifically for established private companies (past Series B round and >$25M raised to date). Please note, registration fees will remain the same, however, a discounted rate has been created for the private company presentation fee, which can be found on our Registration Pages.
Registration and presentation fees can be found here.
Presentations are 25 minutes in length for Public companies and 13 minutes for Private companies and PAGs.
To see a list of 2013 presenting companies, please click here.
For questions regarding company presentations, please visit the Presenter Resource Center, or contact Jennifer Fernandez.